1. MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, Chintoh A, Remington GJ, Taylor VH, Müeller DJ, Graff-Guerrero A, Hahn MK. Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. Front Psychiatry. 2018 Dec 5;9:622.
2. Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017 Apr;47(6):1030-1040.
3. Kowalchuk C, Castellani LN, Chintoh A, Remington G, Giacca A, Hahn MK. Antipsychotics and glucose metabolism: how brain and body collide. Am J Physiol-Endocrinol Metab. 2018 Jul 3;316(1):E1–15.
4. Cooper SJ, Reynolds GP. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol (Oxf). 2016;1–32.
5. Bomboy KT, Graber JS, Wallis EP. Improved Prescriber Adherence to Guidelines on Antipsychotic Medication Management Through Increased Access to Metabolic Monitoring Forms. J Am Psychiatr Nurses Assoc. 2020 Feb 13;1078390320906196.
6. Koch J, Thomas, CJ. Using lipid guidelines to manage metabolic syndrome for patients taking an antipsychotic. Ellingrod VL, editor. Curr Psychiatry. 2016 Jul;15(7).
7. Laugharne J, Waterreus AJ, Castle DJ, Dragovic M. Screening for the metabolic syndrome in Australia: a national survey of psychiatrists’ attitudes and reported practice in patients prescribed antipsychotic drugs. Australas Psychiatry. 2016 Feb 1;24(1):62–6.
8. Xu H, Zhuang X. Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review. Neuropsychiatr Dis Treat. 2019 Jul 22;15:2087–99.
9. Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Børglum AD, et al. Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study. Am J Psychiatry. 2017 Jan 20;174(7):686–94.
10. Freyberg Z, Aslanoglou D, Shah R, Ballon JS. Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. Front Neurosci. 2017 Jul 28;11:432.
11. Benarroch L, Kowalchuk C, Wilson V, Teo C, Guenette M, Chintoh A, Nesarajah Y, Taylor V, Selby P, Fletcher P, Remington GJ, Hahn MK. Atypical antipsychotics and effects on feeding: from mice to men. Psychopharmacology (Berl). 2016 Jul;233(14):2629-53.
12. Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, Stubbs B, Vancampfort D, De Hert M, Olfson M, Kahl KG, Martin A, Guo JJ, Lane HY, Sung FC, Liao CH, Arango C, Correll CU. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2016 Mar;73(3):247-59.
13. Del Campo A, Bustos C, Mascayano C, Acuña-Castillo C, Troncoso R, Rojo LE. Metabolic Syndrome and Antipsychotics: The Role of Mitochondrial Fission/Fusion Imbalance. Front Endocrinol (Lausanne). 2018 Apr 23;9:144.
14. Ijaz S, Bolea B, Davies S, Savović J, Richards A, Sullivan S, et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry. 2018 Sep 3;18(1):275.
15. Lui K, Randhawa G, Totten V, Smith AE, Raese J. Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record|Prim Care Companion. Prim Care Companion CNS Disord. 2016 Jan 28;18(1):6–13.
16. Zheng W, Zheng Y-J, Li X-B, Tang Y-L, Wang C-Y, Xiang Y-Q, et al. Efficacy and Safety of Adjunctive Aripiprazole in Schizophrenia: Meta-Analysis of Randomized Controlled Trials. J Clin Psychopharmacol. 2016 Dec;36(6):628–636.
17. Marteene W, Winckel K, Hollingworth S, Kisely S, Gallagher E, Hahn M, et al. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opin Drug Saf. 2019 Dec 2;18(12):1149–60.
18. Guijarro SF, Pomarol‐Clotet E, Muñoz MCR, García CM, López EE, Guijarro RF, et al. Effectiveness of a community-based nurse-led lifestyle-modification intervention for people with serious mental illness and metabolic syndrome. Int J Ment Health Nurs. 2019;28(6):1328–37.